Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide injection site pain comparison between DV3396 and PDS290
NL-OMON48226Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-blind trial of semaglutide in obesity, Overweight and type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Intensity of injection site pain. Started Jun 2019; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON48226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48226.